强化淋巴清除化疗后人源化抗CD19-CAR-T治疗难治/复发性B-ALL的疗效与安全性
主要不良事件为1-2级细胞因子释放综合征(18例)和3级细胞因子释放综合征(5例),无细胞因子释放综合征相关死亡。
要点
- 强化淋巴清除化疗后人源化抗CD19-CAR-T治疗R/R B-ALL的完全缓解率较高。
- 细胞因子释放综合征多为1-2级,3级细胞因子释放综合征可控,无细胞因子释放综合征相关死亡。
- 输注日骨髓白血病细胞比例及IL-6、TNF-α、IL-8峰值与细胞因子释放综合征级别相关。
核心结论
- 强化淋巴清除化疗可降低疾病负荷,后续人源化抗CD19-CAR-T治疗在R/R B-ALL中应答率高且毒性可控。
研究设计与样本
- 研究纳入23例难治/复发性B细胞急性淋巴细胞白血病患者,CAR-T输注前12天接受氟达拉滨联合中剂量阿糖胞苷强化化疗预处理。
主要发现
- 18例发生1-2级细胞因子释放综合征,5例发生3级细胞因子释放综合征,无患者死于细胞因子释放综合征。
- 仅1例在输注后24天死于巨细胞病毒感染所致呼吸衰竭。
- 输注日骨髓白血病细胞比例及IL-6、TNF-α、IL-8峰值与细胞因子释放综合征级别相关。
临床怎么用
- 对R/R B-ALL可考虑强化淋巴清除化疗后行人源化抗CD19-CAR-T治疗,需监测细胞因子释放综合征及感染。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We studied the efficacy and safety of humanized CAR-T therapy following intensive chemotherapy for refractory/relapsed (R/R) acute lymphoblastic leukaemia (B-ALL). Twenty-three patients with R/R B-ALL were pretreated with intensive chemotherapy (fludarabine combined with medium-dose cytarabine) 12 days before CAR-T therapy. Adverse events (AEs), curative effects, infection indicators and cytokine release syndrome (CRS) were monitored. Each of the 23 patients received a dose of 1·0 × 106 cells/kg CAR-T cell infusion on day 0. After 14 days, 19 patients (82·61%) achieved complete response (CR) or CR with incomplete count recovery. No survival benefit was achieved with consolidative haematopoietic stem-cell transplantation (HSCT), with a median follow-up of 14·0 months (range, 1·5-21·0 months). The notable AEs were grade 1-2 CRS in 18 patients, while the other five patients were grade 3 CRS. No patients died of CRS. Only one patient died of respiratory failure due to cytomegalovirus infection 24 days after infusion. The proportion of leukaemic cells in bone marrow on infusion day and the peaks of IL-6, TNF-α and IL-8 levels were correlated with CRS levels. A lower disease burden was achieved by intensive lymphodepleting chemotherapy, and the subsequent CAR-T therapy had a high response and manageable toxicity. Trial registration: The patients were enrolled in a clinical trial of ChiCTR-ONN-16009862, and ChiCTR1800019622.
引用
- Wang J, Mou N, Yang Z, et al. Efficacy and safety of humanized anti-CD19-CAR-T therapy following intensive lymphodepleting chemotherapy for refractory/relapsed B acute lymphoblastic leukaemia. Br J Haematol. 2020. PMID: 32232846. doi:10.1111/bjh.16623
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。